Select Publications
Journal articles
2018, 'A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve', Oncologist, 23, pp. 203 - 213, http://dx.doi.org/10.1634/theoncologist.2017-0297
,2018, 'Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer', Clinical Cancer Research, 24, pp. 569 - 580, http://dx.doi.org/10.1158/1078-0432.CCR-17-1621
,2018, 'Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients', Gynecologic Oncology, 148, pp. 79 - 85, http://dx.doi.org/10.1016/j.ygyno.2017.10.036
,2018, 'Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer', Quality of Life Research, 27, pp. 59 - 74, http://dx.doi.org/10.1007/s11136-017-1729-8
,2018, 'Medicare-funded cancer genetic tests: A note of caution clinicians need appropriate education and support in keeping pace with the genomics revolution', Medical Journal of Australia, 209, pp. 193 - 196.e1, http://dx.doi.org/10.5694/mja17.01124
,2018, 'Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis', Therapeutic Advances in Medical Oncology, 10, http://dx.doi.org/10.1177/1758835918788500
,2018, 'The importance of patient-reported outcomes in clinical trials and strategies for future optimization', PATIENT-RELATED OUTCOME MEASURES, 9, pp. 353 - 367, http://dx.doi.org/10.2147/PROM.S156279
,2018, 'The value of participating in clinical trials: The whole is greater than the sum of its parts', Medical Journal of Australia, 209, http://dx.doi.org/10.5694/mja17.01266
,2018, 'Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)', Gynecologic Oncology, 148, pp. 36 - 41, http://dx.doi.org/10.1016/j.ygyno.2017.10.019
,2018, 'Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: Randomized phase II study', Annals of Oncology, 29, pp. 154 - 161, http://dx.doi.org/10.1093/annonc/mdx505
,2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', Annals of Oncology, 29, pp. x24 - x25, http://dx.doi.org/10.1093/annonc/mdy487.042
,2018, 'Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study', Annals of Oncology, 29, pp. x28 - x28, http://dx.doi.org/10.1093/annonc/mdy487.007
,2018, 'Tumour profiling for treatment of patients with ovarian cancers', Pathology, 50, pp. S77 - S77, http://dx.doi.org/10.1016/j.pathol.2017.12.200
,2017, 'Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial', Annals of Oncology, 28, pp. 2733 - 2740, http://dx.doi.org/10.1093/annonc/mdx491
,2017, 'Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference', Annals of Oncology, 28, pp. viii30 - viii35, http://dx.doi.org/10.1093/annonc/mdx449
,2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet, 390, pp. 1949 - 1961, http://dx.doi.org/10.1016/S0140-6736(17)32440-6
,2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 390, pg 1949, 2017)', LANCET, 390, pp. 1948 - 1948, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413823200030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer', Familial Cancer, 16, pp. 461 - 469, http://dx.doi.org/10.1007/s10689-017-9977-x
,2017, 'Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers', European Journal of Cancer, 84, pp. 114 - 120, http://dx.doi.org/10.1016/j.ejca.2017.07.004
,2017, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial', The Lancet Oncology, 18, pp. 1274 - 1284, http://dx.doi.org/10.1016/S1470-2045(17)30469-2
,2017, 'Reducing uncertainty: Predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer—The GCIG symptombenefit study', Oncologist, 22, pp. 1117 - 1124, http://dx.doi.org/10.1634/theoncologist.2017-0047
,2017, 'Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients', European Journal of Cancer, 82, pp. 237 - 246, http://dx.doi.org/10.1016/j.ejca.2017.05.010
,2017, 'Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma', Cancer Discovery, 7, pp. 984 - 998, http://dx.doi.org/10.1158/2159-8290.CD-17-0419
,2017, 'Erratum to: The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols (Quality of Life Research, (2016), 25, 10, (2457-2465), 10.1007/s11136-016-1339-x)', Quality of Life Research, 26, pp. 2249 - 2250, http://dx.doi.org/10.1007/s11136-017-1578-5
,2017, 'Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: An AURELIA substudy', Annals of Oncology, 28, pp. 1849 - 1855, http://dx.doi.org/10.1093/annonc/mdx229
,2017, 'Traceback: A proposed framework to increase identification and genetic counseling of BRCA1 and BRCA2 mutation carriers through family-based outreach', Journal of Clinical Oncology, 35, pp. 2329 - 2337, http://dx.doi.org/10.1200/JCO.2016.70.3439
,2017, 'Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', JAMA, 317, pp. 2402 - 2416, http://dx.doi.org/10.1001/jama.2017.7112
,2017, 'Factors Associated with Deciding between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study', Obstetrical and Gynecological Survey, 72, pp. 336 - 337, http://dx.doi.org/10.1097/OGX.0000000000000451
,2017, 'Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer', International Journal of Gynecological Cancer, 27, pp. 900 - 906, http://dx.doi.org/10.1097/IGC.0000000000000978
,2017, 'Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', Journal of Clinical Oncology, 35, pp. 5533 - 5533, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5533
,2017, 'Phase I study of olaparib (O), in combination with oral cyclophosphamide (C), in patients (pts) with metastatic triple negative breast cancer (TNBC) and recurrent high grade serous ovarian cancer (OVCA).', Journal of Clinical Oncology, 35, pp. 1104 - 1104, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.1104
,2017, 'Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer', Best Practice and Research: Clinical Obstetrics and Gynaecology, 41, pp. 126 - 138, http://dx.doi.org/10.1016/j.bpobgyn.2016.11.004
,2017, 'The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: A systematic review', Human Reproduction, 32, pp. 1033 - 1045, http://dx.doi.org/10.1093/humrep/dex027
,2017, 'A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy', Therapeutic Advances in Medical Oncology, 9, pp. 269 - 285, http://dx.doi.org/10.1177/1758834016687260
,2017, 'Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: Recurrent disease', Annals of Oncology, 28, pp. 727 - 732, http://dx.doi.org/10.1093/annonc/mdw663
,2017, 'Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue.', Journal of Pain and Symptom Management, http://dx.doi.org/10.1016/j.jpainsymman.2017.03.015
,2017, 'What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study', Cancer, 123, pp. 985 - 993, http://dx.doi.org/10.1002/cncr.30414
,2017, 'A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: Design and rationale', Future Oncology, 13, pp. 307 - 320, http://dx.doi.org/10.2217/fon-2016-0412
,2017, 'A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: Implications for generalisability and clinical practice', Journal of Patient-Reported Outcomes, 1, http://dx.doi.org/10.1186/s41687-017-0008-3
,2017, 'Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer', Oncotarget, 8, pp. 47154 - 47160, http://dx.doi.org/10.18632/oncotarget.17005
,2017, 'Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required', American Journal of Surgical Pathology, 41, pp. 1433 - 1442, http://dx.doi.org/10.1097/PAS.0000000000000909
,2017, 'Resisting RECISTV uniformity versus clinical validity', International Journal of Gynecological Cancer, 27, pp. 1619 - 1627, http://dx.doi.org/10.1097/IGC.0000000000001062
,2017, 'Comparative Efficacy And Safety Of Olaparib 300 Mg Tablets Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients With Platinum-Sensitive Relapsed Germline BRCA-Mutated Ovarian Cancer (PSROC)', Value in Health, 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.088
,2017, 'Comparative Efficacy And Safety of Olaparib 400 Mg Capsules Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients with Platinum-Sensitive Relapsed Non-Germline BRCA-Mutated Ovarian Cancer (PSROC)', Value in Health, 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.087
,2017, 'Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)', Annals of Oncology, 28, pp. v331 - v331, http://dx.doi.org/10.1093/annonc/mdx372.002
,2017, 'Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study', Obstetrical & Gynecological Survey, 72, pp. 336 - 337, http://dx.doi.org/10.1097/ogx.0000000000000451
,2017, 'Genome-wide analyses identify common variants associated with macular telangiectasia type 2.', Nat Genet, 49, pp. 559 - 567, http://dx.doi.org/10.1038/ng.3799
,2017, 'Is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?', Annals of Oncology, 28, pp. v411 - v411, http://dx.doi.org/10.1093/annonc/mdx376.023
,2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', Annals of Oncology, 28, pp. v130 - v130, http://dx.doi.org/10.1093/annonc/mdx367.023
,2016, '70-Gene signature in early-stage breast cancer', New England Journal of Medicine, 375, pp. 2199 - 2200, http://dx.doi.org/10.1056/NEJMc1612048
,